Former Gilead Sciences Head of Clinical Trial Disclosure and Data Transparency Joins MMS and TrialAssure as Director of Global Transparency Strategy and Compliance

Bringing more than 20 years of clinical development experience, Vaillant has led various functions across clinical development at Gilead Sciences, Ambit Biosciences, Novartis, Amgen, and Pharmacia. An innovator in the Clinical Trial Disclosure and Data Transparency space, he has developed and implemented processes, technologies, and systems that enable more effective, efficient, and secure sharing of clinical trial information.

“MMS and its technology, the TrialAssure suite of applications for facilitating transparency and patient engagement, are leading the effort of enhancing transparency in the drug development space. The addition of Kelly Vaillant to guide these efforts is paramount in developing and refining future innovations,” says Michelle Gayari, Executive Director of Global Operations. “His expertise is well established, and the vision and leadership that Kelly brings is critical as we strive to create a more transparent future in pharma.”

Vaillant’s responsibilities include:

• Leading and advancing the group’s overall transparency vision, strategy, and innovation
• Providing transparency consulting, strategic advice, and operational execution in drug, device, or diagnostic developments
• Providing technical expertise on regulatory requirements and health authority guidance for transparency and clinical trial disclosure activities
• Assisting clients and colleagues in navigating and training on clinical trial transparency regulations, processes, and systems
• Bringing a “Design for Transparency” approach to ensure alignment across the organization

“I wanted to join a team at the forefront of pharmaceutical innovation, and MMS and its TrialAssure technology exceed that mark,” said Kelly Vaillant. “I plan to implement transformative strategies that will build upon the innovative legacy of the organization, while at the same time encouraging industry-wide changes that promote greater levels of data transparency. If I can assist in developing strategies and implementing tools related to responsible data sharing that will speed research and allow for better medical decisions, I would consider myself successful.”

TrialAssure recently announced free use of its flagship TrialAssure REGISTRY product for academic institutions, and the company was recently named Data Solution of the Year—Healthcare in the 2020 Data Breakthrough Awards.

Learn more about TrialAssure’s transparency leadership at www.trialassure.com/.

About MMS

MMS is an award-winning, data-focused CRO that supports the pharmaceutical, biotech, and medical device industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience and a data-driven approach to drug development make MMS a valuable CRO partner, creating compelling submissions that meet rigorous regulatory standards. With a global footprint across four continents, MMS maintains a 97 percent customer satisfaction rating, and the company has been recognized as a leading CRO in Global Health & Pharma’s international awards programs from 2018-2020. For more information, visit www.mmsholdings.com or follow MMS on LinkedIn.

About TrialAssure

TrialAssure – the technology arm of MMS Holdings – is an award-winning, global clinical trial disclosure and transparency reporting suite with unmatched experience in helping clients navigate complex regulatory submission and reporting challenges. TrialAssure helps meet regulatory compliance goals through a flexible, scalable, and streamlined platform that regularly adapts to ever-changing clinical trial disclosure requirements. Established in 2009, the TrialAssure suite was built from the ground up as a single, integrated transparency system, and it is continually strengthened by the experience of leading pharmaceutical industry compliance experts. For more information, visit: www.trialassure.com or follow TrialAssure on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200416005061/en/